Economic burden of hepatitis C-associated diseases: Europe, Asia Pacific, and the Americas

References

• Lavanchy D. The global burden of hepatitis C Liver. Int 2009;29(1 Suppl):74–81
   PubMed Web of Science ®Google Scholar
• Poynard T, Yuen MF, Ratziu V, et al. Viral hepatitis C. Lancet 2003;362:2095-100
   PubMed Web of Science ®Google Scholar
• El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999;340:745-50
   PubMed Web of Science ®Google Scholar
• Seeff LB, Hoofnagle JH. National Institutes of Health Consensus Development Conference: management of hepatitis C: 2002. Hepatology 2002;36:S1-S20
   PubMedGoogle Scholar
• Afdhal NH. The natural history of hepatitis C. Semin Liver Dis 2004;24:3-8
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Guidelines for viral hepatitis surveillance and case management. Atlanta, GA: U.S. Dept. of Health, Education, and Welfare, Public Health Service, 2005
   Google Scholar
• Daniels D, Grytdal S, Wasley A. Surveillance for acute viral hepatitis-United States, 2007. MMWR Surveill Summ 2009;58:1-27
   PubMedGoogle Scholar
• Thomas DL, Seeff LB. Natural history of hepatitis C. Clin Liver Dis 2005;9:383-98
   PubMedGoogle Scholar
• McQuillan GM, Alvarez Martin E, Everhart JE. Viral hepatitis. In: Everhart JE, ed. Digestive diseases in the United States: epidemiology and impact. Washington, D.C.: US Department of Health and Human Services, Public Health Service, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 1994
   Google Scholar
• Kamal SM. Acute hepatitis C: a systematic review. Am J Gastroenterol 2008;103:1283-97
   PubMed Web of Science ®Google Scholar
• Postma MJ, Wiessing L, Jager J. Updated healthcare estimates for drug-related hepatitis C infections in the European Union. In: Jager J, Limburg W, Kretzschmar M, et al., eds. Hepatitis C and injecting drug use: impact, costs and policy options. Luxembourg: Office for Official Publications of the European Communities, 2004. p 203–16
   Google Scholar
• El Khoury A, Klimack WK, Wallace C, et al. Economic burden of hepatitis C-associated diseases in the United States. J Viral Hepat 2011;19:153-60
   PubMedGoogle Scholar
• Kershenobich D, Razavi HA, Cooper CL, et al. Applying a system approach to forecast the total HCV-infected population size - model validation using US data. Liver Int 2011;31(2 Suppl):4-17
   PubMedGoogle Scholar
• Consumer Price Index, Bureau of Labor Statistics, United States Department of Labor. 2010. http://www.bls.gov/cpi/data.htm. Accessed November 23, 2010
   Google Scholar
• Brown K, Crofts N. Health care costs of a continuing epidemic of hepatitis C virus infection among injecting drug users.. Aust N Z J Public Health 1998;22:384-8
   PubMedGoogle Scholar
• Shiell A, Brown S, Farrell GC. Hepatitis C: an economic evaluation of extended treatment with interferon. Med J Aust 1999;171:189-93
   PubMedGoogle Scholar
• Gadiel D, Applied Economics Pty Ltd. Economic evaluation of hepatitis C in Australia [electronic resource]/report prepared for the Australian Government Department of Health and Ageing by Applied Economics Pty Ltd, written by David Gadiel. Australia Department of Health and Ageing, 2005. http://www.health.gov.au/internet/main/publishing.nsf/Content/B24AB78E97822CACCA2571CA0000E270/$File/hepc-econeval.pdf. Accessed January 10, 2011
   Google Scholar
• Shiell A, Briggs A, Farrell GC. The cost effectiveness of alpha interferon in the treatment of chronic active hepatitis C. Med J Aust 1994;160:268-72
   PubMed Web of Science ®Google Scholar
• Siebert U, Sroczynski G, Aidelsburger P, et al. Clinical effectiveness and cost effectiveness of tailoring chronic hepatitis C treatment with peginterferon alpha-2b plus ribavirin to HCV genotype and early viral response: a decision analysis based on German guidelines. Pharmacoeconomics 2009;27:341-54
   PubMedGoogle Scholar
• Fonseca MC, Araujo GT, Axia Bio Consulting, Sao Paulo, Brazil. Medical resource use and direct medical cost of chronic hepatitis C virus infection (HCVI) in Brazil, [PGI15 poster abstract and presentation]. ISPOR Eighth European Congress 2005, Florence, Italy. ISPOR 2005;8:122A–3A
   Google Scholar
• Fonseca MC, Araujo GT, Araujo DV. Cost effectiveness of peginterferon alfa-2B combined with ribavirin for the treatment of chronic hepatitis C in Brazil.. Braz J Infect Dis 2009;13:191-9
   PubMedGoogle Scholar
• El Saadany S, Coyle D, Giulivi A, et al. Economic burden of hepatitis C in Canada and the potential impact of prevention. Results from a disease model. Eur J Health Econ 2005;6:159-65
   PubMedGoogle Scholar
• Taylor MC, Greig PD, Detsky AS, et al. Factors associated with the high cost of liver transplantation in adults. Can J Surg 2002;45:425-34
   PubMedGoogle Scholar
• Myers RP, Liu M, Shaheen AA. The burden of hepatitis C virus infection is growing: a Canadian population-based study of hospitalizations from 1994 to 2004. Can J Gastroenterol 2008;22:381-7
   PubMed Web of Science ®Google Scholar
• Pageaux GP, Souche B, Perney P, et al. Results and cost of orthotopic liver transplantation for alcoholic cirrhosis. Transplant Proc 1993;25:1135-6
   PubMedGoogle Scholar
• Jusot JF, Colin C. Cost-effectiveness analysis of strategies for hepatitis C screening in French blood recipients. Eur J Public Health 2001;11:373-9
   PubMedGoogle Scholar
• Fourquet F, Le GC, Rufat P, et al. [Medical and economic evaluation of organ transplantation in France. The example of liver transplantation]. Rev Epidemiol Sante Publique 2001;49:259-72
   PubMedGoogle Scholar
• Loubiere S, Rotily M, Moatti JP. Prevention could be less cost-effective than cure: the case of hepatitis C screening policies in France. Int J Technol Assess Health Care 2003;19:632-45
   PubMedGoogle Scholar
• Azoulay D, Linhares MM, Huguet E, et al. Decision for retransplantation of the liver: an experience- and cost-based analysis. Ann Surg 2002;236:713-21
   PubMed Web of Science ®Google Scholar
• Wasem J, Sroczynski G, Aidelsburger P, et al. [Health economics of chronic infectious diseases: the example of hepatitis C]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2006;49:57-63
   PubMedGoogle Scholar
• Kraus TW, Mieth M, Schneider T, et al. Cost distribution of orthotopic liver transplantation: single-center analysis under DRG-based reimbursement. Transplantation 2005;80:S97-S100
   PubMedGoogle Scholar
• Sullivan SD, Craxi A, Alberti A, et al. Cost effectiveness of peginterferon alpha-2a plus ribavirin versus interferon alpha-2b plus ribavirin as initial therapy for treatment-naive chronic hepatitis C. Pharmacoeconomics 2004;22:257-65
   PubMed Web of Science ®Google Scholar
• Tramarin A, Gennaro N, Compostella FA, et al. HCV screening to enable early treatment of hepatitis C: a mathematical model to analyse costs and outcomes in two populations. Curr Pharm Des 2008;14:1655-60
   PubMed Web of Science ®Google Scholar
• Filipponi F, Pisati R, Cavicchini G, et al. Cost and outcome analysis and cost determinants of liver transplantation in a European National Health Service hospital. Transplantation 2003;75:1731-6
   PubMedGoogle Scholar
• Iwasaki Y, Tanaka H, Ikeada H, et al. Efficacy and cost-effectiveness of consensus interferon monotherapy with high-dose induction for hepatitis C patients with genotype 2. Scand J Gastroenterol 2010;46:79-90
   Google Scholar
• Younossi ZM, Singer ME, McHutchison JG, et al. Cost effectiveness of interferon alpha2b combined with ribavirin for the treatment of chronic hepatitis. C. Hepatology 1999;30:1318-24
   Google Scholar
• Bennett WG, Inoue Y, Beck JR, et al. Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis. C. Ann Intern Med 1997;127:855-65
   PubMed Web of Science ®Google Scholar
• Ishida K, Imai H, Ogasawara K, et al. Cost-utility of living donor liver transplantation in a single Japanese center. Hepatogastroenterology 2006;53:588-91
   PubMed Web of Science ®Google Scholar
• Kogure T, Ueno Y, Kawagishi N, et al. The model for end-stage liver disease score is useful for predicting economic outcomes in adult cases of living donor liver transplantation. J Gastroenterol 2006;41:1005-10
   PubMedGoogle Scholar
• Bonsel GJ, Essink-Bot ML, de Charro FT, et al. Orthotopic liver transplantation in The Netherlands. The results and impact of a medical technology assessment. Health Policy 1990;16:147-61
   PubMedGoogle Scholar
• Oostenbrink JB, Kok ET, Verheul RM. A comparative study of resource use and costs of renal, liver and heart transplantation. Transpl Int 2005;18:437-43
   PubMedGoogle Scholar
• van Agthoven M, Metselaar HJ, Tilanus HW, et al. A comparison of the costs and effects of liver transplantation for acute and for chronic liver failure. Transpl Int 2001;14:87-94
   PubMed Web of Science ®Google Scholar
• Sheerin IG, Green FT, Sellman JD. The costs of not treating hepatitis C virus infection in injecting drug users in New Zealand. Drug Alcohol Rev 2003;22:159-67
   PubMed Web of Science ®Google Scholar
• Buti M, Casado MA, Fosbrook L, et al. Cost-effectiveness of combination therapy for naive patients with chronic hepatitis C. J Hepatol 2000;33:651-8
   PubMed Web of Science ®Google Scholar
• Pereira A, Sanz C. A model of the health and economic impact of posttransfusion hepatitis C: application to cost-effectiveness analysis of further expansion of HCV screening protocols. Transfusion 2000;40:1182-91
   PubMedGoogle Scholar
• Kim WR, Poterucha JJ, Hermans JE, et al. Cost-effectiveness of 6 and 12 months of interferon-alpha therapy for chronic hepatitis C. Ann Intern Med 1997;127:866-74
   PubMed Web of Science ®Google Scholar
• Sennfalt K, Reichard O, Hultkrantz R, et al. Cost-effectiveness of interferon alfa-2b with and without ribavirin as therapy for chronic hepatitis C in Sweden. Scand J Gastroenterol 2001;36:870-6
   PubMedGoogle Scholar
• Bernfort L, Sennfalt K, Reichard O. Cost-effectiveness of peginterferon alfa-2b in combination with ribavirin as initial treatment for chronic hepatitis C in Sweden. Scand J Infect Dis 2006;38:497-505
   PubMed Web of Science ®Google Scholar
• Lidgren M, Hollander A, Weiland O, et al. Productivity improvements in hepatitis C treatment: impact on efficacy, cost, cost-effectiveness and quality of life. Scand J Gastroenterol 2007;42:867-77
   PubMed Web of Science ®Google Scholar
• Sagmeister M, Renner EL, Mullhaupt B, et al. Simulation of hepatitis C based on a mandatory reporting system. Eur J Gastroenterol Hepatol 2002;14:25-34
   PubMed Web of Science ®Google Scholar
• Sagmeister M, Mullhaupt B, Kadry Z, et al. Cost-effectiveness of cadaveric and living-donor liver transplantation. Transplantation 2002;73:616-22
   PubMedGoogle Scholar
• Lin WA, Tarn YH, Tang SL. Cost-utility analysis of different peg-interferon alpha-2b plus ribavirin treatment strategies as initial therapy for naive Chinese patients with chronic hepatitis C. Aliment Pharmacol Ther 2006;24:1483-93
   PubMed Web of Science ®Google Scholar
• Shepherd J, Waugh N, Hewitson P. Combination therapy (interferon alfa and ribavirin) in the treatment of chronic hepatitis C: a rapid and systematic review. Health Technol Assess 2000;4:1-67
   PubMedGoogle Scholar
• Grieve R, Roberts J, Wright M, et al. Cost effectiveness of interferon alpha or peginterferon alpha with ribavirin for histologically mild chronic hepatitis C. Gut 2006;55:1332-8
   PubMed Web of Science ®Google Scholar
• Grishchenko M, Grieve RD, Sweeting MJ, et al. Cost-effectiveness of pegylated interferon and ribavirin for patients with chronic hepatitis C treated in routine clinical practice. Int J Technol Assess Health Care 2009;25:171-80
   PubMed Web of Science ®Google Scholar
• Steinke DT, Weston TL, Morris AD, et al. Epidemiology and economic burden of viral hepatitis: an observational population based study. Gut 2002;50:100-5
   PubMedGoogle Scholar
• Stein K, Rosenberg W, Wong J. Cost effectiveness of combination therapy for hepatitis C: a decision analytic model. Gut 2002;50:253-8
   PubMed Web of Science ®Google Scholar
• Longworth L, Young T, Buxton MJ, et al. Midterm cost-effectiveness of the liver transplantation program of England and Wales for three disease groups. Liver Transpl 2003;9:1295-307
   PubMed Web of Science ®Google Scholar
• Burroughs AK, Blake J, Thorne S, et al. Comparative hospital costs of liver transplantation and the treatment of complications of cirrhosis. A prospcetive study. Eur J Gastroenterol Hepatol 1992;4:123-8
   Google Scholar
• Foxton MR, Al-Freah MA, Portal AJ, et al. Increased model for end-stage liver disease score at the time of liver transplant results in prolonged hospitalization and overall intensive care unit costs. Liver Transpl 2010;16:668-77
   PubMedGoogle Scholar
• Wong JB, Nevens F. Cost-effectiveness of peginterferon alfa-2b plus ribavirin compared to interferon alfa-2b plus ribavirin as initial treatment of chronic hepatitis C in Belgium. Acta Gastroenterol Belg 2002;65:110-1
   PubMed Web of Science ®Google Scholar
• van der Hilst CS, Ijtsma AJ, Slooff MJ, et al. Cost of liver transplantation: a systematic review and meta-analysis comparing the United States with other OECD countries. Med Care Res Rev 2009;66:3-22
   PubMedGoogle Scholar
• Hoffmann V, Richter GM, Funk H, et al. [Liver transplantation and diagnostic radiology: socioeconomic aspects]. Rofo 1996;165:113-7
   PubMedGoogle Scholar
• Burroughs AK, Blake J, Thorne S, et al. Comparative hospital costs of liver transplantation and the treatment of complications of cirrhosis. A prospcetive study. Eur J Gastroenterol Hepatol 1992;4:123-8
   Google Scholar